AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine ...

The National Academies of Sciences, Engineering, and Medicine will convene an ad hoc study Committee on Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary ...

IO Biotech's co-founder presented advancements in cancer vaccines at the 2025 AACR Annual Meeting, highlighting innovative therapeutic strategies. IO Biotech, a clinical-stage biopharmaceutical ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on preparation ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new ...

Moleculin Biotech ( (MBRX)) has issued an announcement. On November 13, 2025, Moleculin Biotech announced that 60% of the target subjects have consented to participate in its pivotal Phase 2B/3 ...

Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 ...

This meeting will serve as a kick-off for the National Academies consensus study Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary Biotechnology. This me ...